Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.72+0.14 (+0.96%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.58
Open14.65
Bid14.40 x 1300
Ask14.73 x 800
Day's Range14.60 - 14.73
52 Week Range13.17 - 17.43
Volume4,157,514
Avg. Volume2,583,603
Market Cap45.855B
Beta (5Y Monthly)1.00
PE Ratio (TTM)11.31
EPS (TTM)1.30
Earnings DateN/A
Forward Dividend & Yield0.80 (5.60%)
Ex-Dividend DateSep 29, 2021
1y Target Est17.76
  • American City Business Journals

    The Petri Dish: Taiho acquires Cullinan cancer subsidiary in $405M deal

    The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.

  • Reuters

    Japan's Takeda forecasts rebound despite full-year profit drop

    Japan's Takeda Pharmaceutical Co said on Wednesday its 12-month operating profit slid 9.5%, although the country's largest drugmaker forecast a rebound for the current year. Chief Executive Christophe Weber said that core operating profit, which strips out impairments and other non-recurring items, would likely exceed 1 trillion yen this fiscal year, and the company's financials would become clearer now that its 2019 absorption of Shire Plc is complete. Takeda is domestically producing the COVID-19 vaccine, developed by Novavax Inc, which was approved by Japanese regulators last month.

  • Business Wire

    Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022

    OSAKA, Japan, May 11, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength across its key business areas.

Advertisement
Advertisement